AstraZeneca Unit Owes $180 Million-Plus in Syntimmune Case (1)

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to commercialize a drug connected to an acquisition priced at up to $1.2 billion.

A Delaware judge ordered Alexion Pharmaceuticals Inc. to pay $181 million in damages, plus interest, to former shareholders of Syntimmune Inc., which Alexion bought in a 2018 transaction that provided for payments of up to $800 million based on post-deal triggers. AstraZeneca subsequently acquired Alexion for $39 billion in 2021.

The judge, Vice Chancellor Morgan T. Zurn, found Alexion liable last year for multiple breaches of the Syntimmune ...